Nuvation Bio (NUVB) Enterprise Value (2020 - 2026)
Nuvation Bio (NUVB) posted quarterly Enterprise Value of -$533.7 million for Q1 2026, down 15.61% year-over-year from -$632.4 million in Q1 2025, and down 0.85% quarter-over-quarter from -$529.2 million in Q4 2025.
Nuvation Bio (NUVB) Enterprise Value (2020 - 2026) Analysis & Trends
Nuvation Bio (NUVB) has reported Enterprise Value for 7 consecutive years, with -$533.7 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Enterprise Value fell 15.61% year-over-year to -$533.7 million; the TTM figure through Mar 2026 stood at -$533.7 million (down 15.61% YoY), while the FY2025 annual figure was -$529.2 million, down 5.28% from the prior year.
- Enterprise Value retreated to -$533.7 million in Q1 2026 per NUVB's latest filing, from -$529.2 million in the prior quarter.
- Across five years, Enterprise Value topped out at -$461.7 million in Q1 2025 and bottomed at -$737.7 million in Q1 2022.
- Historically, Enterprise Value has averaged -$599.5 million across 5 years, with a median of -$607.7 million in 2025.
- Annual changes were most pronounced in 2025 — Enterprise Value advanced 22.66% — and 2026, when it dropped 15.61%.
- Nuvation Bio's Enterprise Value stood at -$661.0 million in 2022, then gained by 7.53% to -$611.2 million in 2023, then advanced by 17.76% to -$502.7 million in 2024, then dropped by 5.28% to -$529.2 million in 2025, then dropped by 0.85% to -$533.7 million in 2026.
- Business Quant data shows NUVB's Enterprise Value at -$533.7 million in Q1 2026, -$529.2 million in Q4 2025, and -$549.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | -7.85 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -7.99 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | -5.18 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -3.94 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | -5.10 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -8.46 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 2.12 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -3.31 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -1.16 Bn |
| 10 | Nuvation Bio | 2.16 Bn | 2.16 Bn | 30.78 Mn | -660.96 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -660.96 Mn |
| Mar 31, 2026 | -533.73 Mn |
| Dec 31, 2025 | -529.21 Mn |
| Sep 30, 2025 | -549.05 Mn |
| Jun 30, 2025 | -607.72 Mn |
| Mar 31, 2025 | -461.68 Mn |
| Dec 31, 2024 | -502.69 Mn |
| Sep 30, 2024 | -549.14 Mn |
| Jun 30, 2024 | -577.17 Mn |
| Mar 31, 2024 | -596.98 Mn |
| Dec 31, 2023 | -611.21 Mn |
| Sep 30, 2023 | -619.34 Mn |
| Jun 30, 2023 | -630.90 Mn |
| Mar 31, 2023 | -646.61 Mn |
| Dec 31, 2022 | -661.01 Mn |
| Sep 30, 2022 | -673.95 Mn |
| Jun 30, 2022 | -703.80 Mn |
| Mar 31, 2022 | -737.70 Mn |
| Dec 31, 2021 | -765.39 Mn |
| Sep 30, 2021 | -791.78 Mn |